110 related articles for article (PubMed ID: 11676196)
1. Antiischemic properties of fasudil in experimental models of vasospastic angina.
Sato S; Ikegaki I; Asano T; Shimokawa H
Jpn J Pharmacol; 2001 Sep; 87(1):34-40. PubMed ID: 11676196
[TBL] [Abstract][Full Text] [Related]
2. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.
Masumoto A; Mohri M; Shimokawa H; Urakami L; Usui M; Takeshita A
Circulation; 2002 Apr; 105(13):1545-7. PubMed ID: 11927519
[TBL] [Abstract][Full Text] [Related]
3. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina.
Otsuka T; Ibuki C; Suzuki T; Ishii K; Yoshida H; Kodani E; Kusama Y; Atarashi H; Kishida H; Takano T; Mizuno K
Coron Artery Dis; 2008 Mar; 19(2):105-10. PubMed ID: 18300747
[TBL] [Abstract][Full Text] [Related]
4. Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina.
Utsunomiya T; Satoh S; Ikegaki I; Toshima Y; Asano T; Shimokawa H
Br J Pharmacol; 2001 Dec; 134(8):1724-30. PubMed ID: 11739249
[TBL] [Abstract][Full Text] [Related]
5. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.
Otsuka T; Ibuki C; Suzuki T; Ishii K; Kodani E; Atarashi H; Kishida H; Takano T
Circ J; 2006 Apr; 70(4):402-8. PubMed ID: 16565555
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery.
Inokuchi K; Ito A; Fukumoto Y; Matoba T; Shiose A; Nishida T; Masuda M; Morita S; Shimokawa H
J Cardiovasc Pharmacol; 2004 Sep; 44(3):275-7. PubMed ID: 15475822
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.
Satoh S; Utsunomiya T; Tsurui K; Kobayashi T; Ikegaki I; Sasaki Y; Asano T
Life Sci; 2001 Aug; 69(12):1441-53. PubMed ID: 11531167
[TBL] [Abstract][Full Text] [Related]
8. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
Mohri M; Shimokawa H; Hirakawa Y; Masumoto A; Takeshita A
J Am Coll Cardiol; 2003 Jan; 41(1):15-9. PubMed ID: 12570938
[TBL] [Abstract][Full Text] [Related]
9. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.
Fukumoto Y; Mohri M; Inokuchi K; Ito A; Hirakawa Y; Masumoto A; Hirooka Y; Takeshita A; Shimokawa H
J Cardiovasc Pharmacol; 2007 Mar; 49(3):117-21. PubMed ID: 17414222
[TBL] [Abstract][Full Text] [Related]
10. Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats.
Demiryürek S; Kara AF; Celik A; Babül A; Tarakçioglu M; Demiryürek AT
Eur J Pharmacol; 2005 Dec; 527(1-3):129-40. PubMed ID: 16307738
[TBL] [Abstract][Full Text] [Related]
11. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
[TBL] [Abstract][Full Text] [Related]
12. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo.
Shimokawa H; Morishige K; Miyata K; Kandabashi T; Eto Y; Ikegaki I; Asano T; Kaibuchi K; Takeshita A
Cardiovasc Res; 2001 Jul; 51(1):169-77. PubMed ID: 11399259
[TBL] [Abstract][Full Text] [Related]
13. Comparison of anti-anginal effect of cilnidipine with those of nicardipine and nifedipine in the vasopressin-induced angina model of rats.
Cao X; Nakamura Y; Wada T; Izumi-Nakaseko H; Ando K; Zhu B; Xu B; Takahara A; Saitoh M; Sugiyama A
Heart Vessels; 2016 Dec; 31(12):2045-2052. PubMed ID: 27194426
[TBL] [Abstract][Full Text] [Related]
14. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.
Shimokawa H; Hiramori K; Iinuma H; Hosoda S; Kishida H; Osada H; Katagiri T; Yamauchi K; Yui Y; Minamino T; Nakashima M; Kato K
J Cardiovasc Pharmacol; 2002 Nov; 40(5):751-61. PubMed ID: 12409984
[TBL] [Abstract][Full Text] [Related]
15. Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
Satoh Si; Ikegaki I; Toshima Y; Watanabe A; Asano T; Shimokawa H
Life Sci; 2002 Nov; 72(1):103-12. PubMed ID: 12409149
[TBL] [Abstract][Full Text] [Related]
16. The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit.
Yamamoto Y; Ikegaki I; Sasaki Y; Uchida T
J Cardiovasc Pharmacol; 2000 Feb; 35(2):203-11. PubMed ID: 10672851
[TBL] [Abstract][Full Text] [Related]
17. Expression of Rho-kinase (ROCK-1 and ROCK-2) and its substantial role in the contractile activity of the sheep ureter.
Levent A; Büyükafsar K
Br J Pharmacol; 2004 Oct; 143(3):431-7. PubMed ID: 15351780
[TBL] [Abstract][Full Text] [Related]
18. Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice.
Steioff K; Rütten H; Busch AE; Plettenburg O; Ivashchenko Y; Löhn M
Eur J Pharmacol; 2005 Apr; 512(2-3):247-9. PubMed ID: 15840411
[TBL] [Abstract][Full Text] [Related]
19. In vivo dilatation of the ductus arteriosus by Rho kinase inhibition in the rat.
Momma K; Toyoshima K; Sun F; Nakanishi T
Neonatology; 2009; 95(4):324-31. PubMed ID: 19077393
[TBL] [Abstract][Full Text] [Related]
20. Effect of fasudil on macrovascular disorder-induced endothelial dysfunction.
Shah DI; Singh M
Can J Physiol Pharmacol; 2006; 84(8-9):835-45. PubMed ID: 17111028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
